Cannabinoids and pain.

Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol (2004) 1.49

Endocannabinoid mechanisms of pain modulation. AAPS J (2006) 1.28

Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer (2008) 1.09

The pharmacotherapy of chronic pain: a review. Pain Res Manag (2006) 1.01

Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2. Oncotarget (2016) 0.87

Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology (2008) 0.85

Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats. Inflamm Res (2012) 0.79

Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix. Neuropsychopharmacology (2015) 0.76

Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy. J Neurophysiol (2014) 0.76

Regulation of transcription by a protein methyltransferase. Science (1999) 7.22

Ultralong single-wall carbon nanotubes. Nat Mater (2004) 3.83

The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J (1999) 2.44

Frequent Imprecise Excision among Reversions of a P Element-Caused Lethal Mutation in Drosophila. Genetics (1984) 2.35

Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A (1999) 2.31

Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem (2000) 2.05

Chromosome rearrangement by ectopic recombination in Drosophila melanogaster: genome structure and evolution. Genetics (1991) 1.96

Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol (1998) 1.95

Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol (1999) 1.93

Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer (2000) 1.79

Clinical analysis and literature review of massive duodenal diverticular bleeding. World J Surg (2001) 1.79

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes (1997) 1.70

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab (1998) 1.44

Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol (2000) 1.43

Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1. Mol Cell Biol (1999) 1.40

Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res (2001) 1.39

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther (2001) 1.36

Effects of phosphodiesterase inhibitors on spontaneous electrical activity (slow waves) in the guinea-pig gastric muscle. J Physiol (1995) 1.25

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus. Pharm Res (2001) 1.22

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. Br J Clin Pharmacol (2001) 1.19

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys (2001) 1.16

Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br J Pharmacol (2009) 1.11

Laparoscopic cholecystectomy for cholelithiasis in a patient with situs inversus totalis. Endoscopy (1992) 1.11

Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol (1997) 1.11

Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci (2001) 1.09

Acute colonic intramural hematoma due to blunt abdominal trauma. Int Surg (2000) 1.07

Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet (1999) 1.07

Haemoglobin, neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma: development and validation in 3,237 patients from a single institution. Clin Oncol (R Coll Radiol) (2013) 1.06

The neurobiology of cannabinoid analgesia. Life Sci (1999) 1.02

Surgical resection of primary hepatocellular carcinoma extending to adjacent organ(s). Eur J Surg Oncol (1996) 1.01

Molecular cloning of suppressor of sable, a Drosophila melanogaster transposon-mediated suppressor. Mol Cell Biol (1986) 1.01

Modulation of molecular targets to enhance radiation. Clin Cancer Res (2000) 0.99

Molecular and genetic organization of the suppressor of sable and minute (1) 1B region in Drosophila melanogaster. Genetics (1989) 0.98

Consequences of metabolic inhibition in smooth muscle isolated from guinea-pig stomach. J Physiol (1997) 0.96

Effects of cromakalim on the electrical slow wave in the circular muscle of guinea-pig gastric antrum. Br J Pharmacol (1993) 0.96

Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res (1995) 0.95

PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression. Oncogene (2009) 0.95

2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. J Med Chem (1998) 0.94

Single amino acid changes alter the repair specificity of Drosophila Rrp1. Isolation of mutants deficient in repair of oxidative DNA damage. J Biol Chem (1994) 0.93

Recombinant human fibrinogen and sulfation of the gamma' chain. Biochemistry (1991) 0.93

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther (2001) 0.93

Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther (2013) 0.91

Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon hepatitis B virus genome insertion. Oncogene (1998) 0.91

Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids (2002) 0.90

A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs. Biopharm Drug Dispos (1994) 0.90

Characterization of the nuclease activity of Drosophila Rrp1 on phosphoglycolate- and phosphate-modified DNA 3'-termini. Biochemistry (1995) 0.89

Drosophila Rrp1 complements E. coli xth nfo mutants: protection against both oxidative and alkylation-induced DNA damage. Nucleic Acids Res (1993) 0.89

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol (1999) 0.88

Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci (2001) 0.88

Affinity cleavage at the putative metal-binding site of pigeon liver malic enzyme by the Fe(2+)-ascorbate system. Biochemistry (1994) 0.88

Characterization of the apurinic endonuclease activity of Drosophila Rrp1. Biochemistry (1993) 0.88

Immunoreactive endorphin peptides and prolactin in umbilical vein and maternal blood. Am J Obstet Gynecol (1981) 0.87

Expression of Drosophila Rrp1 protein in Escherichia coli. Enzymatic and physical characterization of the intact protein and a carboxyl-terminally deleted exonuclease-deficient mutant. J Biol Chem (1993) 0.87

Kinetic mechanism of the endogenous lactate dehydrogenase activity of duck epsilon-crystallin. Arch Biochem Biophys (1991) 0.87

A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clin Exp Dermatol (2009) 0.85

Functional roles of the N-terminal amino acid residues in the Mn(II)-L-malate binding and subunit interactions of pigeon liver malic enzyme. Protein Eng (1997) 0.85

ATRA-induced pseudotumour cerebri--one case report. Kaohsiung J Med Sci (1998) 0.84

Cecal perforation presenting as abdominal-wall necrotizing fasciitis. Pediatr Surg Int (2001) 0.84

Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res (1997) 0.84

Midpoint back-extrapolation method for the rapid estimation of drugs' volume of distribution and dosage adjustment exhibiting multicompartmental characteristics. Int J Clin Pharmacol Ther Toxicol (1980) 0.84

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. J Med Chem (1999) 0.84

Transverse abdominis musculo-peritoneal (TRAMP) flap for the repair of large duodenal defects. J Trauma (1996) 0.84

Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol (2001) 0.83

Mapping of mouse gamma crystallin genes on chromosome 1. Biochem Genet (1988) 0.83

Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res (1999) 0.83

Human placental alkaline phosphatase. An improved purification procedure and kinetic studies. Eur J Biochem (1992) 0.83

Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica (2000) 0.83

Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. Eur J Clin Pharmacol (1982) 0.83

Vitamin A, Vitamin E or beta-carotene status and hepatitis B-related hepatocellular carcinoma. Ann Epidemiol (1993) 0.82

Mapping the antigenic epitopes of human dihydrofolate reductase by systematic synthesis of peptides on solid supports. J Biol Chem (1990) 0.82

Heat treatment of incinerator retired sorbents containing heavy metals. Sci Total Environ (2001) 0.82

Cloning and expression of pigeon liver cytosolic NADP(+)-dependent malic enzyme cDNA and some of its abortive mutants. Arch Biochem Biophys (1994) 0.82

CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Zhongguo Yao Li Xue Bao (1999) 0.82

Involvement of Phe19 in the Mn(2+)-L-malate binding and the subunit interactions of pigeon liver malic enzyme. Biochemistry (1996) 0.82

Superficial parotid lobe-sparing delineation approach: a better method of dose optimization to protect the parotid gland in intensity-modulated radiotherapy for nasopharyngeal carcinoma. Curr Oncol (2013) 0.82

Plasma ethanol, endorphin, and glucose experiment. Lancet (1980) 0.81

Improved oral bioavailability of the hypocholesterolemic DMP 565 in dogs following oral dosing in oil and glycol solutions. Biopharm Drug Dispos (1997) 0.80

Dissociation of pigeon-liver malic enzyme in reverse micelles. Eur J Biochem (1994) 0.80

Pressure Dependence of Superconductivity in Single-Phase K3C60. Science (1991) 0.80

Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population. Clin Pharmacol Ther (1996) 0.80

Optimal strategies for best management practice placement in a synthetic watershed. Environ Monit Assess (2008) 0.79

Sustained contraction produced by caffeine after ryanodine treatment in the circular muscle of the guinea-pig gastric antrum and rabbit portal vein. Br J Pharmacol (1995) 0.79

Conformational stability of the N-terminal amino acid residues of mutated recombinant pigeon liver malic enzymes. Protein Eng (1998) 0.79

Liquid chromatographic-mass spectrometric measurement of the endogenous cannabinoid 2-arachidonylglycerol in the spinal cord and peripheral nervous system. Zhongguo Yao Li Xue Bao (1999) 0.79

Role of the conserved active site residue tryptophan-24 of human dihydrofolate reductase as revealed by mutagenesis. Biochemistry (1991) 0.79

Successful resection of a minute icteric hepatocellular carcinoma--case report. Hepatogastroenterology (1994) 0.78

EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences. Eur J Pharm Sci (2001) 0.78

Triexponential disposition pharmacokinetics of gentamicin in rabbits. Res Commun Chem Pathol Pharmacol (1979) 0.78

Overexpression of a Rrp1 transgene reduces the somatic mutation and recombination frequency induced by oxidative DNA damage in Drosophila melanogaster. Proc Natl Acad Sci U S A (1996) 0.78

Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. J Pharmacokinet Biopharm (1981) 0.78

Endothelin receptors in human and guinea-pig gallbladder muscle. Regul Pept (2001) 0.78

Core/shell structured NaYF4:Yb3+/Er3+/Gd+3 nanorods with Au nanoparticles or shells for flexible amorphous silicon solar cells. Nanotechnology (2012) 0.77

Nonidentity of the cDNA sequence of human breast cancer cell malic enzyme to that from the normal human cell. J Protein Chem (1996) 0.77

Effects of VEGF121 and/or VEGF165 gene transfection on collateral circulation development. J Formos Med Assoc (2000) 0.77

Improved micro-scale high-pressure liquid-chromatographic assay of gentamicin in plasma. Clin Chem (1978) 0.77

Donor leukocyte infusion as salvage therapy in an adult with relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation. J Formos Med Assoc (1998) 0.76

The effect of absorption enhancers on the oral absorption of the GP IIB/IIIA receptor antagonist, DMP 728, in rats and dogs. Pharm Res (1995) 0.76

Pharmacokinetics of the inodilator XB513 in mice, rats, guinea pigs, rabbits, dogs, and monkeys. Biopharm Drug Dispos (1994) 0.75